Nova Eye USA Sales Growth Opportunity
H1 FY24 Global Sales
no
H1 FY23
(Audited)
H2 FY23
FY23
(Audited)
H1 FY24
(unaudited)
Growth on
PCP
US Dollars '000's
USA
Western Europe
3,060
3,587
6,647
5,050
65%
1,331
1,252
2,583
1,255
-6%
Western Europe OEM sale of equipment (1)
China
256
-
256
N/A
1,050
736
1,786
315
-70%
Total
5,697
5,575
11,272
6,620
16%
Focus of sales and marketing investment in USA following launch of iTrack™ Advance in May 2023 with demonstrated growth results.
Investments in marketing outside the USA have been limited.
Western European iTrack™ sales have fallen 6% in 1H FY24 compared to the PCP reflecting the limited sales and marketing investment in
this region (focus on USA).
Sales to China temporarily disrupted in 2023 by medical industry-wide government review of marketing methods.
PCP was impacted by a delivery of previous order scheduled for 30 June 2022 delivery delayed export documentation until 5 July 2022.
(1) Sales in Germany and Europe in the PCP included a OEM sale of a package of iLumin light sources
nova-eye.com | 15View entire presentation